You have open access to this content

EMBO Molecular Medicine

All articles accepted from 14 August 2012 are published under the terms of the Creative Commons Attribution License.   Articles accepted before this date were published under the agreement as stated in the final article.

Cover image for Vol. 6 Issue 4

Edited By: Stefanie Dimmeler (Chief Editor), Roberto Buccione and Céline Carret (EMBO Editors)

Online ISSN: 1757-4684

New nanotech weapons could reduce deaths from bacterial infections
Professor Sunil Shaunak's research draws on new tools from nanotechnology to manipulate the immune system.

September 2012

EMBO Molecular Medicine - New nanotech weapons could reduce deaths from bacterial infections

The thrill of discovery came early in Sunil Shaunak's medical career. While at Duke University in the mid-1980s he remembers looking down a microscope and seeing the virus that eventually explained the AIDS epidemic. Now, after 27 years of treating and researching infectious diseases at the Royal Postgraduate Medical School and then in the Department of Medicine at Imperial, he reflects on a career that has seen AIDS change from a deadly disease to one whose treatment is as routine as that of diabetes.

But infections still take a huge toll on human lives. "Even though doctors have a powerful arsenal of antibiotics, antivirals and antifungals at their disposal, patients are still dying," Professor Shaunak says. The reason, he asserts, is the over-reaction of the patient's immune system to the threat, which doctors call septic shock.

When the body is attacked by a dangerous microbe, cells of the immune system sound the alarm by releasing cytokines - powerful chemicals with a mission to seek and destroy the invader. But some infections like E. coli and salmonella unleash such an excessive cytokine storm that the patient's blood pressure crashes catastrophically, multiple organ failure develops and death is often the result.

"It's a catastrophe that unfolds in front of your eyes," says Professor Shaunak. We do a good job of killing the bug but we do nothing to control the excessive immune response of the patient, he adds. His latest work is the culmination of 10 years research effort to address this neglected aspect of treating an infection.

The team chose to focus their research on the cytokine storm that occurs in the gut in the diarrhoeal disease shigellosis, which causes a life-threatening inflammatory diarrhoea in more than 100 million people worldwide every year. Shigella is a prime example of a microbe that tricks the patient's immune system to over-react massively. The overblown immune response causes the gut wall to rupture, allowing bacteria to invade the body.

The reaction is triggered by features on the outside of bacterial cells called LPS that are recognised by receptors on immune cells. Professor Shaunak's idea was to devise a molecular mimic that binds to the same receptors as LPS, but doesn't trigger a response. The aim would be to reduce the cytokines released to levels that would be helpful rather than harmful.

To find such a mimic, they studied products of nanotechnology called dendrimers. These molecules, whose name derives from the Greek word for tree, are made up of branches of repeating units. Dendrimers are starting to find applications as carriers for delivering drugs into cells, but Professor Shaunak sees a potential far beyond that. He believes that they could become potential drugs in their own right.

By attaching small sugar molecules to the ends of the dendrimers' branches, they made a molecule that could interact with the immune system's main detection system for bacteria. When they tested it in rabbits, they found that it protected the gut wall from the damage caused by shigella infection, and it minimised invasion by bacteria even when antibiotics were not used.

Professor Shaunak's ongoing collaboration with Professor Steve Matthews in the Department of Life Sciences aims to refine the molecule to make it easier to make on a large scale. "We are in new and unchartered waters when it comes to applying dendrimer-based-nanotechnology to infection-related-inflammation," says Professor Shaunak. "Its potential use could be much broader than the diarrhoeal disease shown in this research paper."



Preventing acute gut wall damage in infectious diarrhoeas with glycosylated dendrimers
Ian Teo, Steve M. Toms, Benoit Marteyn, Teresa S. Barata, Peter Simpson, Karen A. Johnston, Pamela Schnupf, Andrea Puhar, Tracey Bell, Chris Tang, Mire Zloh, Steve Matthews, Phillip M. Rendle, Philippe J. Sansonetti and Sunil Shaunak
EMBO Molecular Medicine 2012, 4(9), 866-881

Accompanying Closeup
Dendrimers branch out to support mucosal integrity
Dermot Kelleher
EMBO Molecular Medicine 2012, 4(9), 860-862

Podcast
Listen to Professor Sunil Shaunak
Professor Sunil Shaunak explains how controlling excessive immune responses could reduce deaths from bacterial infections.

Provided by the Imperial College London

SEARCH

SEARCH BY CITATION